<p>Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update)</p>-Reference-Cited by-同舟云学术

Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update)

Published:2020-03 Issue: Volume:Volume 12 Page:2127-2140
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Zhu Yao,Ye Dingwei

Publisher

Informa UK Limited

Subject

Oncology

Reference63 articles.

1. China Anti-Cancer Association Genitourinary Cancer Committee. Expert consensus on diagnosis and treatment of castration-resistant prostate cancer in China. Zhejiang Med. 2016;38(14):1133–1145.

2. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations

3. Cancer statistics in China, 2015

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia;Future Oncology;2024-02-14

2. OCT4‑positive circulating tumor cells may predict a poor prognosis in patients with metastatic castration‑resistant prostate cancer treated with abiraterone plus prednisone therapy;Oncology Letters;2023-09-04

3. Gender bias in shared decision‐making among cancer care guidelines: A systematic review;Health Expectations;2023-04-05

4. Gambogenic acid induces apoptosis and autophagy through ROS ‐mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells;Phytotherapy Research;2022-09-09

5. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma;Molecular Medicine;2022-07-14